Date: 2011-12-06
Type of information: R&D agreement
Compound: Sprint™
Company: Beactica (Sweden) Almac Discovery (UK)
Therapeutic area: undisclosed
Type agreement: R&D
collaboration
services
Action mechanism: Sprint™ is a SPR (surface plasmon resonance)-based small molecule drug discovery platform.
Disease: undisclosed
Details: Beactica, a Swedish fragment-based drug discovery company, has entered into an agreement with Almac Discovery Ltd., an independent member of the Almac Group Ltd. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint™, to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
